These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 28441024)

  • 1. Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2.
    Li M; Li Y; Ludwik KA; Sandusky ZM; Lannigan DA; O'Doherty GA
    Org Lett; 2017 May; 19(9):2410-2413. PubMed ID: 28441024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101.
    Li M; Li Y; Mrozowski RM; Sandusky ZM; Shan M; Song X; Wu B; Zhang Q; Lannigan DA; O'Doherty GA
    ACS Med Chem Lett; 2015 Jan; 6(1):95-9. PubMed ID: 25589938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of SL0101 carbasugar analogues: carbasugars via Pd-catalyzed cyclitolization and post-cyclitolization transformations.
    Shan M; O'Doherty GA
    Org Lett; 2010 Jul; 12(13):2986-9. PubMed ID: 20518547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of carbasugar C-1 phosphates via Pd-catalyzed cyclopropanol ring opening.
    Shan M; O'Doherty GA
    Org Lett; 2008 Aug; 10(16):3381-4. PubMed ID: 18636740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101.
    Mrozowski RM; Sandusky ZM; Vemula R; Wu B; Zhang Q; Lannigan DA; O'Doherty GA
    Org Lett; 2014 Nov; 16(22):5996-9. PubMed ID: 25372628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regioselective Synthesis of a
    Li Y; Sandusky ZM; Vemula R; Zhang Q; Wu B; Fukuda S; Li M; Lannigan DA; O'Doherty GA
    Org Lett; 2020 Feb; 22(4):1448-1452. PubMed ID: 32009414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4'-hydroxy.
    Li Y; Seber P; Wright EB; Yasmin S; Lannigan DA; O'Doherty GA
    Chem Commun (Camb); 2020 Mar; 56(20):3058-3060. PubMed ID: 32048692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the affinity of SL0101 for RSK using structure-based design.
    Mrozowski RM; Vemula R; Wu B; Zhang Q; Schroeder BR; Hilinski MK; Clark DE; Hecht SM; O'Doherty GA; Lannigan DA
    ACS Med Chem Lett; 2012 Feb; 4(2):175-179. PubMed ID: 23519677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
    Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
    Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the activity of the RSK-specific inhibitor, SL0101.
    Smith JA; Maloney DJ; Hecht SM; Lannigan DA
    Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation.
    Lee SJ; Kim SG
    Mol Pharmacol; 2006 Jan; 69(1):385-96. PubMed ID: 16246908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo asymmetric syntheses of SL0101 and its analogues via a palladium-catalyzed glycosylation.
    Shan M; O'Doherty GA
    Org Lett; 2006 Oct; 8(22):5149-52. PubMed ID: 17048865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Implications of RSK1-3 in Human Breast Cancer.
    Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
    Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p90 ribosomal S6 kinase 1 (RSK1) isoenzyme specifically regulates cytokinesis progression.
    Nam HJ; Lee IJ; Jang S; Bae CD; Kwak SJ; Lee JH
    Cell Signal; 2014 Feb; 26(2):208-19. PubMed ID: 24269382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of a potent and selective inhibitor of p90 Rsk.
    Maloney DJ; Hecht SM
    Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
    Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
    Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total synthesis and biological evaluation of neodysiherbaine A and analogues.
    Shoji M; Akiyama N; Tsubone K; Lash LL; Sanders JM; Swanson GT; Sakai R; Shimamoto K; Oikawa M; Sasaki M
    J Org Chem; 2006 Jul; 71(14):5208-20. PubMed ID: 16808508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved synthesis of structural analogues of (-)-epicatechin gallate for modulation of staphylococcal β-lactam resistance.
    Anderson JC; Grounds H; Reeves S; Taylor PW
    Tetrahedron; 2014 May; 70(21):3485-3490. PubMed ID: 24876661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of C6''-modified α-C-GalCer analogues as mouse and human iNKT cell agonists.
    Guillaume J; Seki T; Decruy T; Venken K; Elewaut D; Tsuji M; Van Calenbergh S
    Org Biomol Chem; 2017 Mar; 15(10):2217-2225. PubMed ID: 28221388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.